The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
9–11 June, 2022 | Berlin, Germany | #RFMV2022
Thank you all for attending the second edition of the RFMV conference.
The conference gathered more than 300 delegates from 50 countries representing a diverse mix of world-leading respiratory scientists, clinicians and allied healthcare professionals. Over three days, delegates witnessed 35 scientific and educational sessions featuring cutting-edge clinical and scientific presentations. More than 60 abstracts and cases were presented throughout the conference and were the subject of lively and engaging discussions during the event.
To all chairs, presenters, delegates, partners and staff, this event would not be possible without your contribution. Thank you for your continuous support.
We look forward to seeing you again at #RFMV2024.
Recordings from the RFMV 2022 Conference are now available to registered delegates on the RFMV Conference platform
ERS Assembly 2 Head
My interest as a pulmonologist combining clinical work with doing (clinical) research are in the field of chronic noninvasive ventilation in patients with chronic respiratory failure with different underlying diseases. My research until now has focussed on NIV in COPD and rehabilitation, showing in a randomised controlled trial that NIV is of additional benefit to rehabilitation in patients with severe COPD. Furthermore, I am especially interested in respiratory muscle work and drive, doing research with surface EMG for more than 10 years now. This interesting technique can be applied under different circumstances and is interesting to use for initiation and optimisation of NIV in different patient groups, also neuromuscular disease. I was an ERS fellow at the Cologne Merheim Hospital, Germany, working in the group of Prof. Windisch, an expert in the field of home NIV. More recently, we started to work with nasal high flow therapy, both for clinical use in COVID-19 as in research setting for the home use in COPD.